These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8219367)

  • 1. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition.
    Engerman RL; Kern TS; Garment MB
    J Diabetes Complications; 1993; 7(4):241-5. PubMed ID: 8219367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.
    Robison WG; Kador PF; Kinoshita JH
    Science; 1983 Sep; 221(4616):1177-9. PubMed ID: 6612330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
    Das A; Frank RN; Zhang NL; Samadani E
    Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocin-induced diabetic rat model.
    Akita M; Mizuno K; Matsubara A; Nakano K; Kurono M
    Acta Med Okayama; 1993 Oct; 47(5):299-304. PubMed ID: 8273453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL; Kern TS
    Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galactose-induced retinal microangiopathy in rats.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):490-6. PubMed ID: 7843917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldose reductase activity and basement membrane thickening.
    Frank RN
    Metabolism; 1986 Apr; 35(4 Suppl 1):35-40. PubMed ID: 3083207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
    Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
    J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase and the development of renal disease in diabetic dogs.
    Kern TS; Engerman RL
    J Diabetes Complications; 1999; 13(1):10-6. PubMed ID: 10232704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention of pericyte ghost formation in retinal capillaries by aldose reductase inhibitor in galactose-fed dogs with diabetic retinopathy].
    Akagi Y; Terubayashi H; Ikebe H; Kador PF; Kinoshita JH
    Nippon Ganka Gakkai Zasshi; 1988 Sep; 92(9):1479-84. PubMed ID: 3145681
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
    Vinores SA; Campochiaro PA
    Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between erythrocyte aldose reductase activity and the width of skeletal-muscle capillary basement membrane in insulin-dependent diabetes mellitus.
    Hamada Y; Hammon K; Raskin P
    J Diabetes Complications; 1992; 6(4):242-6. PubMed ID: 1482782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors.
    Kador PF; Akagi Y; Terubayashi H; Wyman M; Kinoshita JH
    Arch Ophthalmol; 1988 Aug; 106(8):1099-102. PubMed ID: 3401138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenetic heterogeneity in retinal capillary basement membrane thickening in the diabetic BB-rat.
    Chakrabarti S; Sima AA
    Diabetologia; 1987 Dec; 30(12):966-8. PubMed ID: 3125081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.
    Robison WG
    Adv Exp Med Biol; 1988; 246():365-72. PubMed ID: 3150650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of myo-inositol treatment on basement membrane thickening in the BB/W-rat retina.
    Chakrabarti S; Sima AA
    Diabetes Res Clin Pract; 1992 Apr; 16(1):13-7. PubMed ID: 1576927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats.
    Vinores SA; McGehee R; Lee A; Gadegbeku C; Campochiaro PA
    J Histochem Cytochem; 1990 Sep; 38(9):1341-52. PubMed ID: 2117624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors.
    Lightman S; Rechthand E; Terubayashi H; Palestine A; Rapoport S; Kador P
    Diabetes; 1987 Nov; 36(11):1271-5. PubMed ID: 3117606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorbinil does not prevent galactose-induced glomerular capillary basement membrane thickening in the rat.
    Das A; Frank RN; Zhang NL
    Diabetologia; 1990 Sep; 33(9):515-21. PubMed ID: 2123806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.